<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01420965</url>
  </required_header>
  <id_info>
    <org_study_id>11C0231</org_study_id>
    <nct_id>NCT01420965</nct_id>
  </id_info>
  <brief_title>Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer</brief_title>
  <official_title>A Pilot Study to Test the Feasibility and Immunologic Impact of Sipuleucel-T (Provenge) Administered With or Without Anti-PD-1 mAb (CT-011) and Low Dose Cyclophosphamide in Men With Advanced Castrate-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Sipuleucel-T is a new treatment for advanced stage prostate cancer. It takes cells from a&#xD;
      person with prostate cancer and treats them in the laboratory. Then it returns the cells to&#xD;
      the person to help the immune system fight the cancer. Sipuleucel-T may be combined with the&#xD;
      drug CT-011 to boost its ability to kill cancer cells. The chemotherapy drug cyclophosphamide&#xD;
      will also be given, either before or after the cells are collected at the start of the&#xD;
      treatment.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To test the effectiveness of Sipuleucel-T, CT-011, and cyclophosphamide for prostate&#xD;
      cancer.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Men at least 18 years of age who have advanced prostate cancer.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a medical history, physical exam, blood and urine&#xD;
           tests, and imaging studies.&#xD;
&#xD;
        -  This study has two parts, with different participants in each part. All participants&#xD;
           will be monitored with frequent blood tests and imaging studies.&#xD;
&#xD;
        -  Part I:&#xD;
&#xD;
        -  Participants will provide cells for the Sipuleucel-T treatment three times. The first&#xD;
           time will be 3 days before the chemotherapy. The second time will be 10 days after&#xD;
           chemotherapy. The third time will be 24 days after chemotherapy.&#xD;
&#xD;
        -  Participants will have one dose of cyclophosphamide the day before the first dose of&#xD;
           Sipuleucel-T.&#xD;
&#xD;
        -  Participants will have Sipuleucel-T about 3 days after each cell donation.&#xD;
&#xD;
        -  Part II:&#xD;
&#xD;
        -  Participants will be in three groups: Sipuleucel-T given alone, given with CT-011, or&#xD;
           given with both cyclophosphamide and CT-011.&#xD;
&#xD;
        -  Participants will provide cells for the Sipuleucel-T treatment three times, as in Part&#xD;
           I.&#xD;
&#xD;
        -  Participants will have Sipuleucel-T about 3 days after each cell donation, and will&#xD;
           receive treatment with the other drugs as directed by the study doctors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  Prostate cancer is the most common cancer and the second leading cause of cancer deaths&#xD;
           among males in most Western countries.&#xD;
&#xD;
        -  Sipuleucel-T, a recently FDA approved treatment for prostate cancer, is designed to&#xD;
           induce an immune response targeted against PAP, an antigen expressed in most prostate&#xD;
           cancers. .&#xD;
&#xD;
        -  Blockade of PD-1/PD-L1 has been shown to enhance the therapeutic efficacy of peptide&#xD;
           cancer vaccines in pre-clinical animal models. CT-011 is a humanized IgG1 kappa&#xD;
           recombinant monoclonal antibody against PD-1 receptor that blocks the interaction of&#xD;
           PD-L1 with PD-1.&#xD;
&#xD;
        -  Preclinical studies demonstrated that CT-011 when administered with low dose&#xD;
           cyclophosphamide led to synergistic antitumor effects when combined with HPV16 E749-57&#xD;
           peptide vaccine.&#xD;
&#xD;
        -  Given the role CT-011 plays in down-regulating peripheral tolerance and the synergistic&#xD;
           relationship it has with cyclophosphamide in doing so, in this study we propose to treat&#xD;
           patients with advanced, castrate-resistant disease with CT-011 and low-dose&#xD;
           cyclophosphamide as adjuvants in combination with Provenge(Trademark) activated cell&#xD;
           vaccine.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  To assess the feasibility of administration of Sipuleucel-T (Provenge(Trademark))&#xD;
           autologous active cellular immunotherapy in combination with low dose cyclophosphamide&#xD;
           in men with advanced castrate-resistant (hormone refractory) prostate cancer.&#xD;
&#xD;
        -  To determine the immune efficacy of Sipuleucel-T (Provenge(Trademark)) autologous active&#xD;
           cellular immunotherapy alone vs. Sipuleucel-T (Provenge(Trademark)) in combination with&#xD;
           CT- 011 vs. Sipuleucel-T (Provenge(Trademark)) in combination with low-dose&#xD;
           cyclophosphamide and CT-011 on the change in PA2024-specific IFN-? ELISPOT responses in&#xD;
           men with advanced, castrate-resistant prostate cancer.&#xD;
&#xD;
        -  Secondary objectives will determine the tolerability and toxicities of the combination&#xD;
           of low-dose cyclophosphamide/CT-011/ Sipuleucel-T (Provenge(Trademark)) and determine in&#xD;
           a preliminary fashion whether this regimen correlates with increased progression-free&#xD;
           survival (PFS) and overall survival (OS) in patients and with growth rate in an&#xD;
           exploratory fashion.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Males greater than or equal to 18 years old with chemotherapy na ve metastatic&#xD;
           progressive castrate-resistant prostate cancer defined as progressive disease (two&#xD;
           consecutively rising PSA values at a minimum of 1-week intervals (2.0 ng/mL is the&#xD;
           minimum starting value for PSA), appearance of one or more new lesions on bone scans,&#xD;
           progressive disease by Recist 1.1).&#xD;
&#xD;
        -  Must meet minimum organ safety requirements and length of time since prior therapy.&#xD;
&#xD;
        -  May not have active infections, autoimmune disease or require immunosuppressive&#xD;
           therapies.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Part 1: Initially the feasibility generating Sipuleucel-T after administration of low dose&#xD;
      cyclophosphamide , and will be evaluated using a standard 3 + 3 design for doses of&#xD;
      cyclophosphamide 250 mg/m2 or 125 mg/m2. Initially 3 patients will receive cyclophosphamide&#xD;
      on day -1 of the first cycle (one day prior to the first infusion of Sipuleucel-T). All&#xD;
      patients will receive Sipuleucel-T cell infusion on Day 0. The Sipuleucel-T cell infusion&#xD;
      will be repeated every two weeks for a total of three cycles. If Sipuleucel-T active cellular&#xD;
      immunotherapy from an apheresis obtained after infusion of cyclophosphamide, which meets the&#xD;
      FDA approved Certificate of Analysis (COA) release criteria from Dendreon, cannot be&#xD;
      generated, a second apheresis will be performed. Failure of two attempts to generate&#xD;
      Sipuleucel-T product after two aphereses at either the 2nd or 3rd scheduled Sipuleucel-T&#xD;
      infusion will be considered failure of one patient to meet release criteria .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Drug supply issues&#xD;
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Feasibility of Provenge Plus Low-dose Cyclophosphamide as Well as the Immune Efficacy of Provenge Alone Versus Provenge Plus Low-dose Cyclophosphamide and Anti PD1 Monoclonal Antibodies (CT011) on the Change in Specific Immune Response.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine Whether the Combination of Low Dose-Cyclophosphamide and Anti PD1 Monoclonal Antibodies (CT-011) With Provenge(tm) Lead to Improvement in Increase Progression Free Survival (PFS) and Overall Survival (OS) in Patients With Advanced, Min...</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sipuleucel-T autologous active cellular immunotherapy only for 3 cycles (cycle = 14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sipuleucel-T for 3 cycles (cycle = 14 days) + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sipuleucel-T for 3 cycles (cycle = 14 days)+ cyclophosphamide (125 or 250mg/m2) IV [first cycle only] + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-011 (Anti-PD1 Antibody)</intervention_name>
    <description>Immune Enhancer</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>Anti-PD1 Antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sipuleucel-T (Provenge)</intervention_name>
    <description>Vaccine</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>Provenge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Low dose- Immune Enhancer</description>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Patients must have histopathological documentation of prostate cancer prior to starting&#xD;
        this study.&#xD;
&#xD;
        Patients must have metastatic progressive castrate-resistant prostate cancer defined as&#xD;
        progressive disease (see below) despite surgical castration or ongoing use of&#xD;
        gonadotropin-releasing hormone agonists with confirmed castrate levels of testosterone.&#xD;
        Criteria of progression for trial eligibility are defined from the Prostate Cancer Clinical&#xD;
        Trials Working Group-253. Clinically progressive prostate cancer must be evidenced and&#xD;
        documented by any of the following parameters:&#xD;
&#xD;
          1. Two consecutively rising PSA values at a minimum of 1-week intervals (2.0 ng/mL is the&#xD;
             minimum starting value for PSA)&#xD;
&#xD;
          2. Appearance of one or more new lesions on bone scans&#xD;
&#xD;
          3. Progressive measurable disease by RECIST 1.1&#xD;
&#xD;
             Patients on flutamide for at least 6 months must have disease progression at least 4&#xD;
             weeks after withdrawal. Patients on bicalutamide or nilutamide for at least 6 months&#xD;
             must have progression at least 6 weeks after withdrawal.2.1.1.4 Performance Status:&#xD;
             ECOG 0-1 or Karnofsky 80-100% (asymptomatic or minimally symptomatic from metastatic&#xD;
             disease).&#xD;
&#xD;
             No previous chemotherapy use.&#xD;
&#xD;
             No therapeutic immunosuppression or immunomodulation altering bone marrow function&#xD;
             within 6 weeks prior to study entry e.g. G-CSF, GM-CSF, EPO, prednisone etc.&#xD;
&#xD;
             Must have adequate:&#xD;
&#xD;
               -  Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to&#xD;
                  1,500/mcl. Platelets greater than or equal to 100,000/mcl.&#xD;
&#xD;
               -  Renal function: Creatinine less than or equal to 1.5 times institutional upper&#xD;
                  limit normal (ULN)&#xD;
&#xD;
               -  Hepatic function: Bilirubin less than or equal to 1.5 x ULN (CTCAE v4.0 grade 1)&#xD;
                  except patients with Gilbert's disease (up to 5.0 mg/dL). SGOT and alkaline&#xD;
                  phosphatase less than or equal to 2.5 x ULN.&#xD;
&#xD;
               -  Normal Cardiac function: ECG with no evidence of arrhythmia, conduction&#xD;
                  abnormality or ischemia. No active coronary artery disease; no New York Heart&#xD;
                  Association class II, III or IV disease; no arrhythmia requiring treatment.&#xD;
&#xD;
             Must willing and able to sign an informed consent document that explains the&#xD;
             neoplastic nature of the disease, the procedures to be followed, the experimental&#xD;
             nature of the treatment, alternative treatment and potential risks and toxicities.&#xD;
&#xD;
             EXCLUSION CRITERIA:&#xD;
&#xD;
             Concurrent treatment with any other cancer therapies including radiation (except&#xD;
             palliative radiation therapy for bone metastases), chemotherapy or other&#xD;
             investigational agent(s). Androgen suppression therapy will be allowed.&#xD;
&#xD;
             History of a second active malignancy in the last 2 years other than non-melanoma skin&#xD;
             cancers.&#xD;
&#xD;
             Patients who have active or history of autoimmune disease/symptom/conditions&#xD;
             including: type I diabetes, rheumatoid arthritis, systemic lupus erythematosus (SLE),&#xD;
             ulcerative colitis, Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis.&#xD;
             Type II diabetes mellitus, vitiligo or stable hypothyroidism are not considered&#xD;
             exclusion criteria.&#xD;
&#xD;
             Patients being chronically treated with immunosuppressive drugs such as cyclosporin,&#xD;
             adrenocorticotropic hormone (ACTH).&#xD;
&#xD;
             Concurrent use of systemic glucocorticoids within 4 weeks prior to trial entry&#xD;
&#xD;
             Patients who have acquired, hereditary, or congenital immunodeficiencies including&#xD;
             cellular immunodeficiencies, hypogammaglobulinemia and dysgammaglobulinemia.&#xD;
&#xD;
             CNS, lung, or liver metastasis, because of the poor prognosis, and potential inability&#xD;
             to meet study endpoints.&#xD;
&#xD;
             Serious active infection at the time of pre-study screening.&#xD;
&#xD;
             Positive HIV or Hepatitis C antibodies or Hepatitis B anti-core antibodies, because&#xD;
             immunotherapies rely on intact immune systems, and toxicities may be exacerbated by&#xD;
             the presence of infection.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir N. Khleif, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907. doi: 10.1158/1055-9965.EPI-10-0437. Epub 2010 Jul 20. Review.</citation>
    <PMID>20647400</PMID>
  </reference>
  <reference>
    <citation>Gittes RF. Carcinoma of the prostate. N Engl J Med. 1991 Jan 24;324(4):236-45. Review.</citation>
    <PMID>1985245</PMID>
  </reference>
  <reference>
    <citation>Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17;321(7):419-24. Erratum in: N Engl J Med 1989 Nov 16;321(20):1420.</citation>
    <PMID>2503724</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>August 19, 2011</study_first_submitted>
  <study_first_submitted_qc>August 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2011</study_first_posted>
  <results_first_submitted>June 18, 2019</results_first_submitted>
  <results_first_submitted_qc>June 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 10, 2019</results_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Samir N. Khleif</investigator_full_name>
    <investigator_title>Cancer Center Director</investigator_title>
  </responsible_party>
  <keyword>Anti PD-1 Monoclonal Antibody</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Autologous Cellular Immunotherapy</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A</title>
          <description>Sipuleucel-T autologous active cellular immunotherapy only for 3 cycles (cycle = 14 days)&#xD;
Sipuleucel-T (Provenge): Vaccine</description>
        </group>
        <group group_id="P2">
          <title>Arm B</title>
          <description>Sipuleucel-T for 3 cycles (cycle = 14 days) + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion&#xD;
CT-011 (Anti-PD1 Antibody): Immune Enhancer&#xD;
Sipuleucel-T (Provenge): Vaccine</description>
        </group>
        <group group_id="P3">
          <title>Arm C</title>
          <description>Sipuleucel-T for 3 cycles (cycle = 14 days)+ cyclophosphamide (125 or 250mg/m2) IV [first cycle only] + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion&#xD;
CT-011 (Anti-PD1 Antibody): Immune Enhancer&#xD;
Sipuleucel-T (Provenge): Vaccine&#xD;
Cyclophosphamide: Low dose- Immune Enhancer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>Sipuleucel-T autologous active cellular immunotherapy only for 3 cycles (cycle = 14 days)&#xD;
Sipuleucel-T (Provenge): Vaccine</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>Sipuleucel-T for 3 cycles (cycle = 14 days) + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion&#xD;
CT-011 (Anti-PD1 Antibody): Immune Enhancer&#xD;
Sipuleucel-T (Provenge): Vaccine</description>
        </group>
        <group group_id="B3">
          <title>Arm C</title>
          <description>Sipuleucel-T for 3 cycles (cycle = 14 days)+ cyclophosphamide (125 or 250mg/m2) IV [first cycle only] + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion&#xD;
CT-011 (Anti-PD1 Antibody): Immune Enhancer&#xD;
Sipuleucel-T (Provenge): Vaccine&#xD;
Cyclophosphamide: Low dose- Immune Enhancer</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine Feasibility of Provenge Plus Low-dose Cyclophosphamide as Well as the Immune Efficacy of Provenge Alone Versus Provenge Plus Low-dose Cyclophosphamide and Anti PD1 Monoclonal Antibodies (CT011) on the Change in Specific Immune Response.</title>
        <time_frame>2 years</time_frame>
        <population>Study discontinued due to drug supply issues; no analysis performed or meaningful data derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Sipuleucel-T autologous active cellular immunotherapy only for 3 cycles (cycle = 14 days)&#xD;
Sipuleucel-T (Provenge): Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Sipuleucel-T for 3 cycles (cycle = 14 days) + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion&#xD;
CT-011 (Anti-PD1 Antibody): Immune Enhancer&#xD;
Sipuleucel-T (Provenge): Vaccine</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Sipuleucel-T for 3 cycles (cycle = 14 days)+ cyclophosphamide (125 or 250mg/m2) IV [first cycle only] + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion&#xD;
CT-011 (Anti-PD1 Antibody): Immune Enhancer&#xD;
Sipuleucel-T (Provenge): Vaccine&#xD;
Cyclophosphamide: Low dose- Immune Enhancer</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Feasibility of Provenge Plus Low-dose Cyclophosphamide as Well as the Immune Efficacy of Provenge Alone Versus Provenge Plus Low-dose Cyclophosphamide and Anti PD1 Monoclonal Antibodies (CT011) on the Change in Specific Immune Response.</title>
          <population>Study discontinued due to drug supply issues; no analysis performed or meaningful data derived.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine Whether the Combination of Low Dose-Cyclophosphamide and Anti PD1 Monoclonal Antibodies (CT-011) With Provenge(tm) Lead to Improvement in Increase Progression Free Survival (PFS) and Overall Survival (OS) in Patients With Advanced, Min...</title>
        <time_frame>2 years</time_frame>
        <population>Study discontinued due to drug supply issues; no analysis performed or meaningful data derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Sipuleucel-T autologous active cellular immunotherapy only for 3 cycles (cycle = 14 days)&#xD;
Sipuleucel-T (Provenge): Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Sipuleucel-T for 3 cycles (cycle = 14 days) + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion&#xD;
CT-011 (Anti-PD1 Antibody): Immune Enhancer&#xD;
Sipuleucel-T (Provenge): Vaccine</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Sipuleucel-T for 3 cycles (cycle = 14 days)+ cyclophosphamide (125 or 250mg/m2) IV [first cycle only] + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion&#xD;
CT-011 (Anti-PD1 Antibody): Immune Enhancer&#xD;
Sipuleucel-T (Provenge): Vaccine&#xD;
Cyclophosphamide: Low dose- Immune Enhancer</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Whether the Combination of Low Dose-Cyclophosphamide and Anti PD1 Monoclonal Antibodies (CT-011) With Provenge(tm) Lead to Improvement in Increase Progression Free Survival (PFS) and Overall Survival (OS) in Patients With Advanced, Min...</title>
          <population>Study discontinued due to drug supply issues; no analysis performed or meaningful data derived.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>Sipuleucel-T autologous active cellular immunotherapy only for 3 cycles (cycle = 14 days)&#xD;
Sipuleucel-T (Provenge): Vaccine</description>
        </group>
        <group group_id="E2">
          <title>Arm B</title>
          <description>Sipuleucel-T for 3 cycles (cycle = 14 days) + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion&#xD;
CT-011 (Anti-PD1 Antibody): Immune Enhancer&#xD;
Sipuleucel-T (Provenge): Vaccine</description>
        </group>
        <group group_id="E3">
          <title>Arm C</title>
          <description>Sipuleucel-T for 3 cycles (cycle = 14 days)+ cyclophosphamide (125 or 250mg/m2) IV [first cycle only] + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion&#xD;
CT-011 (Anti-PD1 Antibody): Immune Enhancer&#xD;
Sipuleucel-T (Provenge): Vaccine&#xD;
Cyclophosphamide: Low dose- Immune Enhancer</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Negative infusion reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Samir Khleif</name_or_title>
      <organization>Georgetown University</organization>
      <phone>(202) 687-0100</phone>
      <email>snk48@georgetown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

